The paediatric inflammatory bowel disease (IBD) can cause malnutrition and growth retardation. Patients with IBD will require life-long treatment but can be limited by the potential adverse events of corticosteroids and anti-TNF agents in children as well as secondary loss of response (LoR) and drug dependence can occur at some time during the lifetime.
GMA use in paediatric IBD patients: Real world experiences (in English)
April 1, 2022
Experience with GMA in paediatric UC is not as extensive as in adult patients. However, several studies have suggested that GMA can be effective and safe in children and adolescents with IBD especially in mild to moderate chronically active UC. It is especially useful in patients that do not respond to or are dependent on corticosteroids, because GMA can help to taper or withdraw them. GMA is also effective after loss of response to immunosuppressants or anti-TNF agents and to substitute toxic drug treatments. In those patients only induction therapy could lead to sustained remission. In addition, no adverse or very mild events have been reported and the technique is well accepted by paediatric patients and their families.
In this workshop different real world experiences with GMA in paediatric patients and the existing evidences supporting its use will be reviewed.
Role of GMA in paediatric IBD: successful cases from our centre. Dra. Ester Donat H. la Fe
GMA in pediatric IBD: Current use. Dra. Elena Creuhá H. Clínico Universitario de Valencia.
Review of the evidence on the use of GMA in IBD: Past, present and future. Dra. Raquel Simó H. Dr. Peset
Contact UsFor more informationContact Us